ABL Diagnostics S.A

ABL Diagnostics S.A is a biotechnology startup founded in 2015. The company specializes in designing, developing, manufacturing, marketing, and supporting molecular biology diagnostic tests for the detection of infectious diseases. ABL Diagnostics has a strong global presence, with a direct or exclusive distributor network in 45 countries. The company has leveraged proprietary expertise and scientific collaborations to develop high-tech genotyping medical devices for chronic infectious diseases such as HIV/AIDS, viral hepatitis, tuberculosis, and, notably, SRAS-CoV-2 (Covid-19). In addition to diagnostic tests, ABL Diagnostics offers complementary products for patient care, including sample collection kits, a specialized electronic medical record system (Nadis®), and medical devices for viral extraction, amplification, sequencing, and laboratory automation. With a €6.27 million revenue in 2021, the company has 25 employees and operates from Paris, Metz, and Marseille. ABL Diagnostics' innovative approach and diverse product portfolio position it as a significant player in the biotechnology sector, addressing critical needs in disease management. For more information, visit https://www.abldiagnostics.com/.